HOME
SEARCH
RSS FEED
SUBSCRIBE
Isolation of Hybridomas Producing Monoclonal Antibodies (MAbs) Inhibitory to Human CYP2J2
Case ID:
TAB-777
Web Published:
12/6/2022
Description:
The National Institutes of Health announces three specific monoclonal antibodies that strongly inhibit and/or immunoblot the human cytochrome P450 2J2 (CYP2J2).
Cytochrome P450s catalyze the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species. The eicosanoids are biosynthesized in numerous tissues including pancreas, intestine, kidney, heart and lung where they are involved in many different biological activities.
MAb 6-5-20-8 selectively inhibits CYP2J2-mediated arachidonic acid metabolism by more than 80% and also immunoblots the enzyme. MAb 6-2-16-1 also selectively inhibits arachidonic acid metabolism by more than 80% but does not immunoblot the enzyme. MAb 5-3-2-2 is not inhibitory but selectively immunoblots the enzyme. These antibodies can be used to identify and quantify inter-individual variation in physiological functions and to study pharmacological drug metabolism in various tissues.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Isolation_of_Hybridomas_Producing_Mo noclonal_Antibodies_(MAbs)_Inhibitory_to_Human_CYP2J2
Category(s):
Collaboration
Therapeutics
Diagnostics
Research Materials
Bookmark this page
Download as PDF
For Information, Contact:
Vidita Choudhry
Technology Development Specialist
NIH Technology Transfer
301-594-4095
vidita.choudhry@nih.gov
Inventors:
Darryl Zeldin
Keywords:
IDXXXX
IXXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2025. All Rights Reserved. Powered by
Inteum